SELB - Selecta Biosciences Inc Stock Price, Fair Value and News

0.84USD-0.01 (-1.18%)Delayed

Market Summary

USD0.84-0.01

Delayed

-1.18%

SELB Stock Price

View Fullscreen

SELB RSI Chart

SELB Valuation

Market Cap

14.9M

Price/Earnings (Trailing)

-0.06

Price/Sales (Trailing)

0.58

EV/EBITDA

0.44

Price/Free Cashflow

-0.25

SELB Price/Sales (Trailing)

SELB Profitability

EBT Margin

-803.94%

Return on Equity

218.21%

Return on Assets

-78.37%

Free Cashflow Yield

-394.62%

SELB Fundamentals

SELB Revenue

Revenue (TTM)

25.9M

Rev. Growth (Yr)

-1.65%

Rev. Growth (Qtr)

-29.35%

SELB Earnings

Earnings (TTM)

-254.9M

Earnings Growth (Yr)

-162.31%

Earnings Growth (Qtr)

68.01%

Breaking Down SELB Revenue

Last 7 days

35.5%

Last 30 days

15.1%

Last 90 days

-22.2%

Trailing 12 Months

-31.7%

How does SELB drawdown profile look like?

SELB Financial Health

Current Ratio

3.03

SELB Investor Care

Buy Backs (1Y)

88.40%

Diluted EPS (TTM)

-12.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	25.9M	0	0	0
2023	82.7M	48.7M	34.5M	26.0M
2022	108.0M	127.6M	123.9M	110.8M
2021	32.0M	47.3M	67.1M	85.1M
2020	9.7M	12.0M	14.3M	16.6M
2019	1.7M	1.7M	1.6M	7.4M
2018	588.3K	969.5K	1.4M	1.7M
2017	6.1M	4.1M	2.2M	207.0K
2016	7.1M	7.8M	7.3M	8.1M
2015	3.8M	4.5M	5.3M	6.0M
2014	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Selecta Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 25, 2023	traber peter g	sold	-747	1.06	-705	chief medical officer
Sep 25, 2023	brunn carsten	sold	-3,107	1.06	-2,932	president and ceo
May 31, 2023	kishimoto takashi kei	gifted	-	-	-53,000	chief scientific officer
May 30, 2023	kishimoto takashi kei	gifted	-	-	-86,000	chief scientific officer
Jan 05, 2023	kishimoto takashi kei	sold	-3,830	1.12919	-3,392	chief scientific officer
Jan 05, 2023	brunn carsten	sold	-15,214	1.12922	-13,473	president and ceo
Jan 05, 2023	traber peter g	sold	-3,912	1.1292	-3,465	chief medical officer
Jan 05, 2023	johnston lloyd p.	sold	-3,830	1.12919	-3,392	chief operations officer
Jan 04, 2023	traber peter g	sold	-9,272	1.13372	-8,179	chief medical officer
Jan 04, 2023	johnston lloyd p.	sold	-7,246	1.13371	-6,392	chief operations officer

Which funds bought or sold SELB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	unchanged	-	-360,187	5,938,810	0.15%
May 16, 2024	JANE STREET GROUP, LLC	added	121	64,553	123,637	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-68.5	-9,372	3,960	-%
May 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	reduced	-96.67	-29,634	488,889	0.07%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-81.12	-298,679	64,696	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-20.64	21,985,700	23,010,800	-%
May 15, 2024	AMERIPRISE FINANCIAL INC	sold off	-100	-242,313	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-42.23	-35,000	44,000	-%
May 15, 2024	Voya Investment Management LLC	reduced	-7.63	-4,432	29,897	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-32.91	-115,459	198,770	-%

Are Funds Buying or Selling SELB?

Are funds buying SELB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SELB

No. of Funds

Unveiling Selecta Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 10, 2024	fmr llc	-	0	SC 13G/A
Apr 12, 2024	springer timothy a	36.4%	6,473,184	SC 13D/A
Apr 10, 2024	kalayoglu murat	19.9%	3,538,386	SC 13D/A
Apr 10, 2024	singer michael	4.3%	769,744	SC 13D/A
Mar 28, 2024	springer timothy a	27.9%	194,189,313	SC 13D/A
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	mangrove partners im, llc	2.59%	4,127,258	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Feb 09, 2024	artal international s.c.a.	6.4%	10,455,849	SC 13G/A
Nov 22, 2023	singer michael	13.9%	26,060,927	SC 13D

Recent SEC filings of Selecta Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	SC 13G/A	Major Ownership Report
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	3	Insider Trading
Apr 12, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Selecta Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Selecta Biosciences Inc News

Latest updates

Selecta Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-29.3%	5,840,000	8,266,000	6,551,000	5,249,000	5,938,000	16,795,000	20,710,000	39,273,000	33,999,000	29,937,000	24,427,000	19,663,000	11,050,000	11,951,000	4,646,000	5,315,333	5,984,667	6,654,000	184,000	246,000	277,000
Operating Expenses	-57.0%	19,188,000	44,598,000	19,616,000	23,887,000	24,319,000	25,291,000	22,309,000	25,413,000	23,226,000	25,859,000	26,396,000	19,211,000	18,208,000	19,849,000	18,380,000	16,367,000	18,822,000	19,224,000	11,794,000	16,248,000	11,866,000
S&GA Expenses	-100.0%	-	22,167,000	6,614,000	6,105,000	5,695,000	6,324,000	5,770,000	6,231,000	5,537,000	5,541,000	5,445,000	4,748,000	5,204,000	4,758,000	4,420,000	5,637,000	4,098,000	4,072,000	3,690,000	4,114,000	4,513,000
R&D Expenses	-56.6%	9,738,000	22,431,000	13,002,000	17,782,000	18,624,000	18,967,000	16,539,000	19,182,000	17,689,000	20,318,000	20,951,000	14,463,000	13,004,000	15,091,000	13,960,000	10,730,000	14,724,000	15,152,000	8,104,000	12,134,000	7,353,000
EBITDA Margin	-0.8%	-7.96	-7.90	0.15	0.24	0.14	0.10	-0.05	-0.05	-0.06	-0.07	-0.97	-1.39	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	1,273,000	752,000	808,000	807,000	802,000	715,000	707,000	711,000	711,000	711,000	711,000	713,000	365,000	205,000	273,000	1,500,000	388,000	400,000	396,000
Income Taxes	-	-	-	-	-	-	-288,000	-321,000	-	-	138,000	15,828,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-196,658,000	-9,002,000	-	-	5,605,000	-8,214,000	-	-	12,377,000	-2,066,000	-	-	-	-9,729,000	-	-	-	-	-	-
EBT Margin	-0.4%	-8.04	-8.01	0.02	0.16	0.09	0.07	-0.08	-0.08	-0.09	-0.11	-1.03	-1.46	-	-	-	-	-	-	-	-	-
Net Income	68.0%	-56,824,000	-177,658,000	-9,002,000	-11,387,000	-21,663,000	5,893,000	-7,893,000	8,601,000	28,778,000	12,239,000	-17,894,000	4,565,000	-24,597,000	-15,446,000	-9,729,000	-24,081,000	-19,620,000	-14,888,000	-11,994,000	-16,394,000	-12,074,000
Net Income Margin	-16.4%	-9.84	-8.45	-1.05	-0.72	-0.18	0.32	0.34	0.25	0.26	-0.30	-0.80	-0.96	-	-	-	-	-	-	-	-	-
Free Cashflow	29.3%	-16,519,000	-23,350,000	-9,215,000	-9,907,000	-8,895,000	-12,060,000	3,917,000	-12,370,000	-12,319,000	-31,738,000	-10,910,000	-6,661,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	6.6%	325	305	106	140	156	166	178	188	146	160	167	181	177	165	181	75.00	89.00	100	40.00	47.00	62.00
Current Assets	22.5%	111	91.00	90.00	123	138	148	160	173	130	144	152	167	163	151	167	61.00	74.00	97.00	36.00	44.00	60.00
Cash Equivalents	36.3%	105	77.00	80.00	112	126	106	113	138	113	114	115	126	125	140	146	60.00	73.00	92.00	34.00	30.00	32.00
Net PPE	13.7%	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00
Goodwill	0%	48.00	48.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-0.6%	442	445	46.00	74.00	81.00	72.00	93.00	98.00	90.00	137	186	185	196	183	188	88.00	98.00	91.00	44.00	47.00	48.00
Current Liabilities	-46.3%	37.00	68.00	20.00	29.00	27.00	25.00	24.00	34.00	39.00	72.00	96.00	87.00	85.00	82.00	77.00	23.00	30.00	35.00	29.00	32.00	33.00
Shareholder's Equity	73.5%	-116	-440	60.00	65.00	75.00	94.00	85.00	90.00	56.00	23.00	-	-	-	-	-	-	-	8.00	-	0.00	15.00
Retained Earnings	-9.3%	-671	-614	-436	-427	-416	-394	-400	-392	-401	-430	-442	-424	-429	-404	-389	-379	-355	-335	-320	-308	-335
Additional Paid-In Capital	212.4%	559	179	502	498	496	493	490	487	462	457	428	425	414	391	386	371	351	349	320	313	312
Shares Outstanding	-96.7%	5.00	162	155	153	153	153	153	149	124	114	113	114	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	129	-	-	-	150	-	-	-	367	-	-	-	248	-	-	-	59.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	31.6%	-15,917	-23,286	-9,215	-9,895	-8,765	-11,849	4,353	-12,271	-11,864	-31,460	-10,746	-6,043	-12,133	-7,250	65,637	-11,808	-11,698	-12,876	-11,122	-7,197	-20,240
Share Based Compensation	-89.9%	1,431	14,144	2,321	3,783	2,276	2,276	2,601	3,564	2,753	2,253	1,904	1,783	1,780	1,236	1,296	1,481	1,409	1,427	1,303	1,251	1,180
Cashflow From Investing	-109.3%	-602	6,497	-	-12.00	28,124	5,489	-29,937	-99.00	9,545	9,722	-1,802	-2,615	-22,445	-166	-286	-154	-135	-9.00	11,512	4,845	-16,119
Cashflow From Financing	205.6%	43,031	14,081	-24,789	-2,586	149	-	612	36,875	1,728	21,156	1,450	8,984	21,307	-190	20,948	-957	-5,370	68,534	5,028	372	31,107

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SELB Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Collaboration and license revenue	$ 5,840	$ 5,938
Operating expenses:
Research and development	9,738	18,624
General and administrative	9,450	5,695
Total operating expenses	19,188	24,319
Operating loss	(13,348)	(18,381)
Investment income	1,164	1,331
Foreign currency transaction, net	0	19
Interest expense	0	(808)
Change in fair value of warrant liabilities	1,042	(4,079)
Change in fair value of contingent value right liability	(39,300)	0
Change in fair value of forward contract liabilities	(6,890)	0
Other income, net	508	255
Net loss	(56,824)	(21,663)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(5)	(22)
Unrealized gain (loss) on marketable securities	0	11
Total comprehensive loss	$ (56,829)	$ (21,674)
Net loss per share:
Basic (in dollars per share)	$ (10.50)	$ (4.24)
Diluted (in dollars per share)	$ (10.50)	$ (4.24)
Weighted-average common shares outstanding:
Basic (in shares)	5,414,020	5,111,518
Diluted (in shares)	5,414,020	5,111,518

SELB Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 103,418	$ 76,911
Accounts receivable	2,006	5,870
Unbilled receivables	2,370	2,981
Prepaid expenses and other current assets	3,315	4,967
Total current assets	111,109	90,729
Non-current assets:
Property and equipment, net	2,402	2,113
Right-of-use asset, net	9,556	10,068
In-process research and development assets	150,600	150,600
Goodwill	48,163	48,163
Long-term restricted cash	1,377	1,377
Investments	2,000	2,000
Total assets	325,207	305,050
Current liabilities:
Accounts payable	2,517	3,150
Accrued expenses and other current liabilities	9,516	15,572
Lease liability	2,229	2,166
Deferred revenue	412	2,311
Warrant liabilities	597	720
Contingent value right liability	21,383	15,983
Forward contract liabilities	0	28,307
Total current liabilities	36,654	68,209
Non-current liabilities:
Lease liability, net of current portion	8,228	8,789
Deferred revenue, net of current portion	0	3,538
Warrant liabilities, net of current portion	4,755	5,674
Contingent value right liability, net of current portion	376,517	342,617
Deferred tax liabilities, net	15,853	15,853
Total liabilities	442,007	444,680
Commitments and contingencies (Note 18)
Series A Preferred Stock, $0.0001 par value; no and $548,375 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no and $435,120.513 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	296,851
Options for Series A Preferred Stock	0	3,703
Stockholders’ deficit:
Preferred stock, value, issued	0	0
Common stock, $0.0001 par value; 350,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 5,515,836 and 5,397,597 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	559,275	179,062
Accumulated deficit	(671,471)	(614,647)
Accumulated other comprehensive loss	(4,605)	(4,600)
Total stockholders’ deficit	(116,800)	(440,184)
Total liabilities, convertible preferred stock, and stockholders’ deficit	325,207	305,050
Series A Preferred Stock
Stockholders’ deficit:
Preferred stock, value, issued	$ 0	$ 0

About Selecta Biosciences Inc

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Carsten Brunn Ph.D.
WEBSITE	https://selectabio.com
INDUSTRY	Biotechnology
EMPLOYEES	64

Selecta Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Selecta Biosciences Inc? What does SELB stand for in stocks?

SELB is the stock ticker symbol of Selecta Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Selecta Biosciences Inc (SELB)?

As of Tue Apr 30 2024, market cap of Selecta Biosciences Inc is 14.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SELB stock?

You can check SELB's fair value in chart for subscribers.

What is the fair value of SELB stock?

You can check SELB's fair value in chart for subscribers. The fair value of Selecta Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Selecta Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SELB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Selecta Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether SELB is over valued or under valued. Whether Selecta Biosciences Inc is cheap or expensive depends on the assumptions which impact Selecta Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SELB.

What is Selecta Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, SELB's PE ratio (Price to Earnings) is -0.06 and Price to Sales (PS) ratio is 0.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SELB PE ratio will change depending on the future growth rate expectations of investors.